Life Sciences Angel Investor & Operator
Investing in
healthcare
founders.
A curated life science network where founders, investors, LPs, and advisors connect. Turning complexity into conviction in early-stage healthcare.
Share what you're building.
For seed-stage life sciences companies seeking an investor who understands science, development, and execution.
Submit Pitch Deck Investors & OperatorsJoin the network.
A growing community of life science founders, investors, advisors, and industry experts. Tell us how you'd like to participate.
Join the Network ReadersLearn how investors think.
Practical writing on fundraising, founder readiness, diligence, and translating healthcare innovation into companies.
Read Journal
About
Turning Complexity into Conviction
I'm Chao Zheng, a pharmaceutical R&D operator, angel investor, and advisor helping life sciences founders, investors, and executives turn complexity into conviction in early-stage healthcare innovation.
I bring experience across discovery research and development, project leadership, strategy, external innovation, and CMC execution. My work focuses on the questions that determine whether promising science can become a durable company: Is the problem meaningful? Is the evidence credible? Is the path realistic? Is the team complete? Are the key risks being reduced in a way that investors, partners, and future acquirers can trust?
ChaosBio exists to bridge scientific innovation and successful company building. Through practical frameworks and informed analysis, I help founders build credibility, help investors evaluate risk, and help healthcare leaders make better decisions at the intersection of science, capital, and execution.
Connect on LinkedInInvestment Lens
Investors fund risk reduction.
Great science matters, but it is rarely the whole story. I look for companies that can turn uncertainty into clear milestones across the science, team, development path, manufacturing, and financing strategy.
Science risk
Compelling biology, differentiated evidence, and a clear reason this approach can matter.
Execution risk
Founders who are coachable, transparent, self-aware, and able to build around their gaps.
Development risk
Milestones that are realistic, fundable, and meaningful to future investors or acquirers.
Manufacturing risk
CMC and scale-up questions addressed early enough to avoid preventable surprises.
Investment Focus
Three areas where I invest.
I focus on seed-stage companies where my pharma R&D background gives founders a real advantage — in diligence, in coaching, and in network.
Therapeutics
Small molecules, biologics, and ATMPs targeting diseases with high unmet medical need.
Medical Devices
Novel medical devices that improve patient outcomes or create new standards of care in medicine.
Digital Health
AI and digital solutions that address clear clinical, workflow, or patient adoption problems.
Portfolio
Companies I've backed.
Seed and early-stage investments in life sciences companies pushing the boundaries of medicine.
